Evidence map›Paper›PMID 39083592›Full record

ArticleInorganic chemistry2024

Multiaction Pt(IV) Complexes: Cytotoxicity in Ovarian Cancer Cell Lines and Mechanistic Studies.

Leila Tabrizi, Alan M Jones, Isolda Romero-Canelon, Andrea Erxleben

Abstract read
In one paragraph

Article in Inorganic chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leila TabriziSchool of Biological and Chemical Sciences, University of Galway, Galway H91 TK33, Ireland.
Alan M JonesSchool of Pharmacy, University of Birmingham, Birmingham B15 2TT, U.K.ORCID 0000-0002-3897-5626
Isolda Romero-CanelonSchool of Pharmacy, University of Birmingham, Birmingham B15 2TT, U.K.ORCID 0000-0003-3847-4626
Andrea ErxlebenSchool of Biological and Chemical Sciences, University of Galway, Galway H91 TK33, Ireland.ORCID 0000-0002-7309-8972

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer has the worst case-to-fatality ratio of all gynecologic malignancies. The main reasons for the high mortality rate are relapse and the development of chemoresistance. In this paper, the cytotoxic activity of two new multiaction platinum(IV) derivatives of cisplatin and oxaliplatin in a panel of ovarian cancer cells is reported.

Indexed as

Antineoplastic AgentsApoptosisDrug Screening Assays, AntitumorOvarian NeoplasmsCell Line, TumorCell ProliferationCell SurvivalCisplatinCoordination ComplexesDose-Response Relationship, DrugFemaleHumansMolecular StructureOrganoplatinum CompoundsReactive Oxygen SpeciesStructure-Activity RelationshipAntineoplastic AgentsCisplatinCoordination ComplexesOrganoplatinum CompoundsReactive Oxygen Species

Identifiers

PMID39083592
PMCPMC11323244

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.